| Literature DB >> 33590892 |
Zhiquan He1, Bohao Wang2, Yi Li1,3, Kai Hu4, Zhijie Yi2, Hongxia Ma1,3, Xingle Li1,3, Wanshen Guo1, Bianli Xu1, Xueyong Huang1,3.
Abstract
Severe fever with thrombocytopenia syndrome (SFTS) is recognized as an emerging infectious disease. This study aimed to investigate the pathogenic mechanism of SFTS. A total of 100 subjects were randomly included in the study. Cytokine levels were detected by enzyme-linked immunosorbent assay and the viral load was detected by micro drop digital PCR. The results showed that levels of interleukin-6 (IL-6), IL-8, IL-10, IFN-inducible protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), transforming growth factor-β1 (TGF-β1), and regulated upon activation normal T cell expressed and secreted factor (RANTES) differed significantly among the SFTS patient group, healthy people group, and asymptomatic infection group (p < .05). Compared to the healthy people group, the patient group had increased cytokine levels (IL-6, IL-10, IP-10, MCP-1, and IFN-γ) but reduced levels of IL-8, TGF-β1, and RANTES (p < .0167). IL-6, IL-8, IL-10, IP-10, MCP-1, MIP-1α, TGF-β1, and the RANTES levels had different trends after the onset of the disease. IL-6, IL-10, IP-10, and MCP-1 levels in severe patients were higher than those in mild patients (p < .05). There was a positive correlation between viral load and IL-6 and IP-10 but a negative correlation between viral load and RANTES. SFTSV could cause a cytokine change: the cytokine levels of patients had different degrees of fluctuation after the onset of the disease. The levels of IL-6 and IL-8 in the asymptomatic infection group were found between the SFTS patients group and the healthy people group. The levels of IL-6, IL-10, IP-10, and MCP-1 in the serum could reflect the severity of the disease, and the levels of IL-6, IP-10, and RANTES were correlated with the viral load.Entities:
Keywords: asymptomatic infected persons; cytokines; patients; severe fever with thrombocytopenia syndrome; viral load
Mesh:
Substances:
Year: 2021 PMID: 33590892 PMCID: PMC8360139 DOI: 10.1002/jmv.26877
Source DB: PubMed Journal: J Med Virol ISSN: 0146-6615 Impact factor: 2.327
Comparison of research subjects in general
| Characteristics | SFTS patient group ( | Healthy people group ( | Asymptomatic infected person group ( | ||
|---|---|---|---|---|---|
| Age, year (mean ± | 65.45 ± 9.22 | 66.57 ± 10.18 | 64.24 ± 8.98 | 1.510 | .222 |
| Sex, | 2.458 | .293 | |||
| Male | 50 (50) | 44 (44) | 39 (39) | ||
| Female | 50 (50) | 56 (56) | 61 (61) | ||
| Marital status, | 1.367 | .505 | |||
| Married | 92 (97) | 87 (87) | 90 (90) | ||
| Unmarried/divorced/widowed | 8 (3) | 13 (13) | 10 (10) | ||
| Occupation, | 2.589 | .274 | |||
| Farmer | 89 (89) | 93 (93) | 86 (86) | ||
| Others | 11 (11) | 7 (7) | 14 (14) |
Characteristics of subjects and cytokine levels included in the study
| Characteristics | SFTS patient group ( | Healthy people group ( | Asymptomatic infected person group ( | ||||
|---|---|---|---|---|---|---|---|
| IL‐6 | 71.39 | 25.32 | 29.80 | <.001 | <.001 | .005 | <.001 |
| (33.35–141.60) | (12.40–29.32) | (17.20–39.56) | |||||
| IL‐8 | 66.28 | 70.50 | 69.27 | <.001 | <.001 | .010 | <.001 |
| (66.02–66.85) | (68.03–76.85) | (66.49–74.21) | |||||
| IL‐10 | 20.29 | 5.19 | 5.56 | <.001 | <.001 | .096 | <.001 |
| (11.09–42.03) | (3.29–6.54) | (4.29–7.19) | |||||
| IP‐10 | 1124.53 | 58.05 | 61.53 | <.001 | <.001 | .327 | <.001 |
| (444.24–2173.64) | (41.99–75.50) | (45.91–79.04) | |||||
| MCP‐1 | 195.40 | 86.83 | 54.22 | <.001 | <.001 | .004 | <.001 |
| (80.68–405.09) | (52.18–126.95) | (35.44–103.75) | |||||
| MIP‐1α | 684.80 | 684.16 | 683.28 | .157 | .001 | .010 | .0011 |
| (682.80–711.08) | (682.85–689.99) | (681.93–686.22) | |||||
| IFN‐γ | 36.86 (18.38–83.93) | 10.36 (3.81–42.01) | 6.06 (3.91–12.72) | .003 | <.001 | .665 | <.001 |
| ( | ( | ( | |||||
| TGF‐β1 | 980.25 | 3654.05 | 4694.88 | <.001 | <.001 | <.001 | <.001 |
| (430.62–1609.65) | (2915.33–4268.67) | (3597.08–5083.66) | |||||
| TNF‐α | 73.78 (27.27–203.28) | 85.72 (40.34–104.05) | 56.95 (36.54–187.91) | .726 | .901 | .767 | .954 |
| ( | ( | ( | |||||
| RANTES | 1236.15 | 1671.83 | 2011.91 | <.001 | <.001 | .033 | <.001 |
| (787.60–1636.08) | (1330.82–2089.53) | (1300.61–2630.62) |
Abbreviations: IFN‐γ, interferon‐γ; IL‐6, interleukin‐6; IP‐10, IFN‐inducible protein‐10; MCP‐1, monocyte chemoattractant protein‐1; MIP‐1α, macrophage inflammatory protein‐1α; RANTES, regulated upon activation normal T cell expressed and secreted factor; TNF‐α, tumor necrosis factor‐α; TGF‐β1, transforming growth factor‐β1.
Note: Unit: pg/ml.
The cytokine levels were measured in SFTS patients on admission.
The SFTS patient group compared with the healthy people group.
The SFTS patient group compared with the asymptomatic infected person group.
The healthy people group compared with the asymptomatic infected person group.
Comparison among the three groups.
Denotes the median (IQ).
Denotes there was a lack of data.
Denotes had statistical differences.
Figure 1Comparison of cytokine levels among the SFTS patient on admission, healthy people group, and asymptomatic infected person groups. Unit: pg/ml. A, IL‐6, (B) IL‐8, (C) IL‐10, (D) IP‐10, (E) MCP‐1, (F) MIP‐1α, (G) IFN‐γ, (H)TGF‐β1, and (I) RANTES. Horizontal bars indicate the group median. *p < .0167 between the patient and asymptomatic infected person groups. **p < .0167 between the healthy people and patient groups, ***p < .0167 between the healthy people and asymptomatic infected person groups. IFN‐γ, interferon‐γ; IL‐6, interleukin‐6; IP‐10, IFN‐inducible protein‐10; MCP‐1, monocyte chemoattractant protein‐1; MIP‐1α, macrophage inflammatory protein‐1α; RANTES, regulated upon activation normal T cell expressed and secreted factor; SFTS, thrombocytopenia syndrome; TGF‐β1, transforming growth factor‐β1
Figure 2Dynamic changes of serum cytokines in 22 mild SFTS patients after onset of the disease
Comparison of demographic and cytokine differences among SFTSV patients relative to the acuity of disease
| Characteristics | Mild disease ( | Severe disease ( | χ2/ | |
|---|---|---|---|---|
| Age, year (mean ± SD) | 65.44 ± 9.47 | 65.50 ± 8.49 | 0.029 | .977 |
| Sex (male) | 41 (52.56%) | 9 (40.91%) | 0.932 | .334 |
| IL‐6 | 55.11 | 133.87 | 14.429 | <.001 |
| (26.85–99.29) | (94.95–204.53) | |||
| IL‐8 | 66.26 | 66.48 | 1.367 | .242 |
| (65.98–66.84) | (66.12–67.11) | |||
| IL‐10 | 18.80 | 99.02 | 14.556 | <.001 |
| (7.36–34.69) | (21.56–159.05) | |||
| IP‐10 | 852.19 | 1944.40 | 10.968 | .001 |
| (345.28–1701.48) | (1125.84–2453.77) | |||
| MCP‐1 | 185.51 | 569.56 | 6.980 | .008 |
| (76.79–230.37) | (105.40–1283.45) | |||
| MIP‐1α | 684.26 | 685.95 | 2.594 | .107 |
| (682.09–710.71) | (683.95–742.47) | |||
| IFN‐γ | 27.69(13.33–50.76) | 103.08 (51.20–212.72) | 19.032 | <.001 |
| ( | ( | |||
| TGF‐β1 | 1116.73 | 588.61 | 2.661 | .103 |
| (442.4–1628.11) | (409.84–1242.41) | |||
| TNF‐α | 44.21(21.93–178.94) | 120.50 (48.08–338.22) | 1.622 | .203 |
| ( | ( | |||
| RANTES | 1260.07 | 1134.79 | 0.020 | .680 |
| (785.09–1687.11) | (815.88–1540.5) |
Note: Unit, pg/ml.
Abbreviations: IFN‐γ, interferon‐γ; IL‐6, interleukin‐6; IP‐10, IFN‐inducible protein‐10; MCP‐1, monocyte chemoattractant protein‐1; MIP‐1α, macrophage inflammatory protein‐1α; RANTES, regulated upon activation normal T cell expressed and secreted factor; SFTSV, thrombocytopenia syndrome virus; TNF‐α, tumor necrosis factor‐α; TGF‐β1, transforming growth factor‐β1.
Denotes the median (IQ).
Denotes there was a lack of data.
Figure 3Correlation between viral load and cytokines. Correlations between variables were assessed using the Pearson test. p < .05 was considered significant. VL, viral load; Lg RNA copies/ml, Log10 RNA copies/ml